EDQM, the European Directorate for the Quality of Medicines and Healthcare, has suspended the following Certificate of Suitability (CEP):
R1-CEP 2002-222-Rev 01 / Stanozolol Micronised.
The manufacturer concerned is:
Edmond Pharma S.R.L.
Via G.B. Grassi 15
20157 Milano, Italy
If the EDQM withdraws or suspends a CEP, the marketing authorisation holder must take the necessary measures to ensure that active substances from the concerned active substance manufacturer are not used, either permanently or for a defined period.
If any medicines on the market contain this active substance from the concerned active substance manufacturer, the marketing authorisation holder must report the product defect to the Danish Health and Medicines Authority at firstname.lastname@example.org.
Please find additional information on EDQM's website.